Title : Protective Efficacy of Hepatitis B Immunoglobulin & Hepatitis B Vaccination in Infants born to HBsAg-positive Mothers
Background: HBV infection is highly endemic in the Philippines. The WHO estimates that the prevalence of HBV is about 1 in 10 people. Moreover, a study in 2013 reported a HBsAg seroprevalence of 16.7%, translating to an estimated 7.3 million Filipino adults. Chronic hepatitis B infection has a significant public health impact in the Philippines because it is a common cause of end stage liver disease and is the leading cause of Hepatocellular carcinoma
Objective: Perinatal transmission of Hepatitis B virus continues to be a global health burden. This study aims to determine the efficacy of Hepatitis B immunoglobulin (HBIG) and Hepatitis B vaccine (HBV) given at birth until completion to infants born to HBsAg positive mothers.
Design: This is a cross-sectional, descriptive study. A quota sampling was used wherein all eligible participants were recruited until the needed sample size was met. To determine the rate of protective efficacy of HBIG and HBV defined by anti-HBs level >10 mIU/mL and negative HBsAg, post-vaccination serologic testing (PVST) was performed
Patients/Participants: Through quota sampling, 50 infants born to HBsAg-positive mothers between January to December 2020 were enrolled in the study. All infants were ages 9-12 months, received Post-exposure prophylaxis within 12 hours of birth and completed Hepatitis B vaccine series.
Results: Of the 50 infants, 2% were immunoprophylaxis failure (positive for HBsAg), 14% were vaccine non-responders (anti-HBs <10mIU/mL), 84% were vaccine responders (anti-HBs ≥10mIU/mL). The factors including gender, birth weight, gestation age, manner of delivery and maternal age did not contribute to the no response to HB vaccination.
Conclusions: HBIG and HB vaccination of infants born to HBsAg-positive mothers were effective and allowed high protection against mother to child transmission. The HBIG and HB vaccination were a well-tolerated and safe regimen to prevent chronic HBV infection. PVST of infants born to HBsAg-positive mothers proved to be an essential strategy to ensure protection for vaccine non-responders and assure appropriate medical care for those infected.
What will audience learn from your presentation?
- With this research, the audience will be able to know the importance of post vaccination serologic testing and timely giving of vaccination among infants of HBsAg positive mothers
- Audience will be able to know how they will approach this kind of patients
- It will help prevent chronic HBV infection among infants born to HBsAg positive mothers